Navigation Links
Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
Date:2/19/2008

tivity are two neurophysiological measurements that have been shown to be closely associated with nicotinic alpha-7 function and schizophrenia.

In November 2007, Memory Pharmaceuticals announced positive Phase 2a data from a clinical trial of MEM 3454 in Alzheimer's disease. MEM 3454 demonstrated a statistically significant effect on cognition at the 5 mg and 15 mg doses on both the primary and key secondary endpoints for that trial. Roche has an option to a worldwide, exclusive license to develop and commercialize MEM 3454 upon the delivery by Memory of the study report of the Phase 2a AD study and the fulfillment of certain additional predefined events. Roche is obligated to make a milestone payment to Memory Pharmaceuticals at the time this option is exercised.

In December 2007, as part of the development program for MEM 3454 in schizophrenia, Memory Pharmaceuticals commenced a Phase 2a clinical trial of MEM 3454 in CIAS. To maintain its license to MEM 3454, Roche would have to make an additional milestone payment to the Company upon completion of the ongoing Phase 2a CIAS trial, which is expected to be completed in the fourth quarter of 2008.

Evoked Potentials in Schizophrenia

Electrophysiology measures have long been used to detect changes in brain activity in patients with schizophrenia. These patients often have a diminished ability to suppress the evoked response to the second of two auditory stimuli, which is known as sensory gating. A number of both preclinical and clinical studies have shown that this abnormality is genetically linked to the nicotinic alpha-7 receptor and can be measured through the P50 auditory evoked response, a positive waveform measured 50 milliseconds after an auditory stimulus. Recent scientific studies have shown that a nicotinic alpha-7 agonist can both improve cognition and improve P50 inhibition, giving rise to the possibility that P50 can be used to track cognitive effects for this class of compounds
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
2. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
3. Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease
4. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... COLORADO SPRINGS, Colo. , July 29, 2014 /PRNewswire-USNewswire/ ... remote-controlled catheter (MARC) which could allow physicians to see ... stroke may hold promise, according to study authors who ... Surgery (SNIS) 11 th Annual Meeting in ... findings stand to advance the field of neurointervention, a ...
(Date:7/29/2014)... NASHVILLE, Tenn. and NEW YORK ... and member of the executive management team of Caremark ... of PBM365 Media ( www.pbm365.com ).  PBM365 is the ... and unbiased reporting, insight, analysis and opinion on ... PBM365 will provide insightful and timely coverage of, ...
(Date:7/29/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence ... Clinical Lab Expo today by unveiling two booths (#1209 ... partnering with customers to redefine the value of the ... that they,re looking for a partner to help them ... offices," said Jack Phillips , president and CEO ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3Drew Crawford Announces Launch of PBM365 Media 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... Inc . announced today that David A. Weber, Ph.D. , ... Board of Directors. Jay Lichter, Ph.D., managing director of Avalon Ventures, ... actively support the company as a member of the Board of ... to the Otonomy team, as his extensive experience in the development ...
... 2010 Amicus Therapeutics (Nasdaq: FOLD ), ... diseases, today announced that it has been awarded a ... Parkinson,s Research (MJFF) for the development of a novel, ...  The $500,000 award will be distributed over a period ...
Cached Medicine Technology:Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 2Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 2Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 4Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 5
(Date:7/29/2014)... (GSA) and the National Center for Creative Aging ... University as the 2014 recipient of the Gene D. ... award recognizes and honors the seminal work of Gene ... and aging shifted the conceptual focus from a problem ... individuals to approach longevity asking what wonders can be ...
(Date:7/29/2014)... boys with fragile X syndrome tend to decline ... of the inherited disorder to date has found. ... social and practical skills, including communication, socialization, and ... dressed. In this study, socialization emerged as a ... that it did not decline as much as ...
(Date:7/29/2014)... More Zeppelin than Zen, the Rock Spa® at Seminole Hard ... complete renovation and, upon its re-opening in the fall, will ... , The Rock Spa® will include an all-new hair and ... hair and nail stylists. Both part time and full time ... given full medical and health benefits, a rare perk in ...
(Date:7/29/2014)... Society of America (GSA) the nation,s largest ... has chosen Laura N. Gitlin, PhD, of the Johns ... 2014 recipient of the M. Powell Lawton Award. ... gerontology that has led to an innovation in gerontological ... barriers, or a public policy change that has led ...
(Date:7/29/2014)... truBrain has created a solution for ... drinks. Think Drinks , available today on Indiegogo, ... conditions for memory, complex reasoning and sustained energy while ... $50,000 over the course of the 30-day campaign. , ... have compounding effects over time when used as a ...
Breaking Medicine News(10 mins):Health News:Charon to receive 2014 Gene D. Cohen Award 2Health News:Socialization relative strength in fragile X longitudinal study 2Health News:Rock Spa® at Seminole Hard Rock Hotel & Casino Tampa Prepares for Expansion 2Health News:Gitlin earns GSA's 2014 M. Powell Lawton Award 2Health News:Focus- and Productivity-Enhancing Beverage Launches Crowdfunding Campaign on Indiegogo 2
... The American College of Radiology (ACR) and Society of ... Obstetricians and Gynecologists, (ACOG) recommendations that women begin getting ... now correspond with those of the American Cancer Society, ... Breast Disease (ASBD) and many other major medical associations ...
... HealthDay Reporter , WEDNESDAY, July 20 (HealthDay News) -- ... disease as a major health threat, fearing its onset nearly ... Germany, Poland, Spain and the United States, the poll also ... to visit a doctor if they or a loved one ...
... HealthDay Reporter , WEDNESDAY, July 20 (HealthDay News) ... players can quantify the force of impact, offering new insight ... collisions may eventually help manufacturers design helmets that are more ... the University of Michigan and lead author of a new ...
... (HealthDay News) -- Premature infants are at greater risk ... hyperactivity and depression, a new study suggests. These ... affecting cortical development as well as neural connectivity, said ... Although "preemies" are at risk for these injuries, the ...
... gene-based test to distinguish harmless from precancerous pancreatic cysts. ... needless surgery to remove the harmless variety. A ... 20 issue of Science Translational Medicine . ... more than a million patients each year, most of ...
... a special fascination for Marlene Zuk , world-class evolutionary ... offer us, she says, a way to understand living things ... "People have strong feelings about insects, and most of those ... at the University of California, Riverside. "But insects let ...
Cached Medicine News:Health News:ACR, SBI support updated ACOG recommendations that women begin annual mammograms at age 40 2Health News:International Poll Shows Many Fear Alzheimer's as Much as Cancer 2Health News:International Poll Shows Many Fear Alzheimer's as Much as Cancer 3Health News:High-Tech Football Helmets Gauge Force of Collision 2Health News:Preemies at Risk for Psychiatric Disorders as Teens, Study Contends 2Health News:Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts 2Health News:Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts 3Health News:'Sex on Six Legs' is focus of UC Riverside biologist's book 2Health News:'Sex on Six Legs' is focus of UC Riverside biologist's book 3Health News:'Sex on Six Legs' is focus of UC Riverside biologist's book 4
Colloidal Gold Conjugated, Protein A - 12 OD...
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Conjugated, Protein G - 12 OD...
Colloidal Gold Sol, 40 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: